公开(公告)号：US11253523B2

公开(公告)日：2022-02-22

申请号：US16817689

申请日：2020-03-13

Applicant: PFIZER INC.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C. Stock

IPC: A61K31/519 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/40

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US09937181B2

公开(公告)日：2018-04-10

申请号：US14211659

申请日：2014-03-14

Applicant: Pfizer Inc.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C Stock

IPC: A61K31/519 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/40

CPC classification number: A61K31/519 ,  A61K9/0004 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2866 ,  A61K9/4891 ,  A61K31/40 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US20180193347A1

公开(公告)日：2018-07-12

申请号：US15915750

申请日：2018-03-08

Applicant: PFIZER INC.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner ,  Manisha Lamba ,  Thomas C. Stock

IPC: A61K31/519 ,  A61K9/48 ,  A61K31/40 ,  A61K9/20 ,  A61K9/28 ,  A61K9/00 ,  A61K45/06

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US20220142927A1

公开(公告)日：2022-05-12

申请号：US17580991

申请日：2022-01-21

Applicant: PFIZER INC.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C. Stock

IPC: A61K9/20 ,  A61K31/519 ,  A61K9/00

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US20200206232A1

公开(公告)日：2020-07-02

申请号：US16817689

申请日：2020-03-13

Applicant: PFIZER INC.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C. Stock

IPC: A61K31/519 ,  A61K31/40 ,  A61K9/48 ,  A61K9/20 ,  A61K9/28 ,  A61K9/00 ,  A61K45/06

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US20140271842A1

公开(公告)日：2014-09-18

申请号：US14211659

申请日：2014-03-14

Applicant: Pfizer Inc.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C Stock

IPC: A61K31/519 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K9/0004 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2866 ,  A61K9/4891 ,  A61K31/40 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

Abstract translation: 本发明涉及tofacitinib的口服缓释制剂及其药学上可接受的盐。 本文描述的制剂具有所需的药代动力学特征。